News | Left Atrial Appendage (LAA) Occluders | July 05, 2016

AtriCure Receives CE Mark for AtriClip PRO2 Device

CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the United States in April 2016

AtriCure, AtriClip PRO2 LAA Exclusion System, CE Mark, left atrial appendage occlusion

July 5, 2016 — AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System, which offers increased functionality to occlude the LAA during minimally-invasive surgical (MIS) procedures. The device was previously launched in April 2016 with U.S. Food and Drug Administration (FDA) 510(k) clearance in the United States.

The addition of the AtriClip PRO2 device has expanded the left atrial appendage product offerings and now provides an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers and a hoopless end effector. These features have improved the ease of use and time it takes to manage the left atrial appendage.

For more information: www.atricure.com


Related Content

News | Atrial Fibrillation

April 13, 2026 — Heart failure is common in people who have atrial fibrillation detected during screening, according to ...

Home April 14, 2026
Home
News | Atrial Fibrillation

April 2, 2026 — Omron Healthcare Co. has launched a randomized controlled trial in collaboration with the University of ...

Home April 03, 2026
Home
News | Atrial Fibrillation

Feb. 9, 2026 — Argá Medtech has announced positive clinical results from the BURST-AF (NCT05572047) first-in-human trial ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Feb. 9, 2026 — Atraverse Medical presented new clinical and preclinical data at AF Symposium 2026 in Boston, further ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Dec. 19, 2025 — Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by ...

Home December 19, 2025
Home
Feature | Atrial Fibrillation | Jeffrey Olgin, M.D.

Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable ...

Home September 12, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...

Home September 08, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders ...

Home September 08, 2025
Home
Feature | Atrial Fibrillation

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at elevated risk for cardiovascular disease.1 ...

Home September 04, 2025
Home
News | Atrial Fibrillation

June 13, 2025 — An international study has shown that targeted online education on atrial fibrillation (AF) for health ...

Home June 16, 2025
Home
Subscribe Now